NLS Biotech article

Sweden has retained its position as the European Union’s most innovative member state, while Denmark ranks second, according to the European Commission’s European Innovation Scoreboard 2026.

BioArctic's partner Eisai has presented new data at the 2026 Alzheimer’s Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer’s disease.

Nasal drug delivery is a dynamic area in pharmaceutical innovation. What was once a route for decongestants and allergy sprays is now being explored for everything from emergency treatments to vaccines – and even shows potential for future central nervous system therapies.

Nasal drug delivery is a dynamic area in pharmaceutical innovation. What was once a route for decongestants and allergy sprays is now being explored for everything from emergency treatments to vaccines – and even shows potential for future central nervous system therapies.

Elicera Therapeutics provides an update on the development of its iTANK-armed CAR T-cell therapy candidate ELC-401 for the treatment of recurrent glioblastoma.

Denmark’s recent regulatory moves are increasingly described as a competitive advantage for the country’s life science sector, as the government aligns national rules with the EU Pharmaceutical Package and the forthcoming Biotech Act, according to analysis from Pharmadanmark and EU policy commentators.